Shattuck Labs, Inc.
COMBINATION THERAPIES COMPRISING TIM-3-BASED CHIMERIC PROTEINS

Abstract:

The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of T-cell immunoglobulin mucin receptor 3 (TIM-3) and an extracellular domain of CD40 Ligand (CD40L) or an extracellular domain of OX40 Ligand (OX40L) that find use in the treatment of disease, such as cancer.